A novel histochemistry assay to assess and quantify focal cytochrome c oxidase deficiency by Simard M-L et al.
Journal of Pathology
J Pathol 2018
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.5084
ORIGINAL PAPER
A novel histochemistry assay to assess and quantify focal
cytochrome c oxidase deficiency
Marie-Lune Simard1, Arnaud Mourier1,2, Laura C Greaves3,4, Robert W Taylor4,5 and James B Stewart1*
1 Max Planck Institute for Biology of Ageing, Cologne, Germany
2 CNRS, Université de Bordeaux, Institut de Biochimie et Génétique Cellulaires, UMR5095, Bordeaux, France
3 Newcastle University LLHW Centre for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
4 Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
5 NHS Highly Specialised Mitochondrial Diagnostic Laboratory, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
*Correspondence to: James B Stewart, Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Strasse 9b, 50931, Cologne, Germany.
E-mail: jstewart@age.mpg.de
Abstract
Defects in the respiratory chain, interfering with energy production in the cell, are major underlying causes of
mitochondrial diseases. In spite of this, the surprising variety of clinical symptoms, disparity between ages of onset,
as well as the involvement of mitochondrial impairment in ageing and age-related diseases continue to challenge
our understanding of the pathogenic processes. This complexity can be in part attributed to the unique metabolic
needs of organs or of various cell types. In this view, it remains essential to investigate mitochondrial dysfunction
at the cellular level. For this purpose, we developed a novel enzyme histochemical method that enables precise
quantification in fresh-frozen tissues using competing redox reactions which ultimately lead to the reduction of
tetrazolium salts and formazan deposition in cytochrome c oxidase-deficient mitochondria. We demonstrate that
the loss of oxidative activity is detected at very low levels – this achievement is unequalled by previous techniques
and opens up new opportunities for the study of early disease processes or comparative investigations. Moreover,
human biopsy samples of mitochondrial disease patients of diverse genotypic origins were used and the successful
detection of COX-deficient cells suggests a broad application for this new method. Lastly, the assay can be adapted
to a wide range of tissues in the mouse and extends to other animal models, which we show here with the fruit
fly, Drosophila melanogaster. Overall, the new assay provides the means to quantify and map, on a cell-by-cell
basis, the full extent of COX deficiency in tissues, thereby expending new possibilities for future investigation.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Defects in mitochondrial oxidative metabolism lead
to human diseases with a broad clinical spectrum.
Symptoms can manifest early or late in life and while
neuromuscular problems are most common, any organ
or tissue can be affected [1–3]. This variability in the
clinical manifestations remains largely unexplained and
great efforts have been put into deciphering what causes
this broad phenotypic expression and tissue specificity
[2].
A powerful approach to investigate the state of the
respiratory chain activity is the use of mitochondrial
enzyme histochemistry. This allows the visualization of
mitochondrial activity without disturbing the structural
integrity of the tissue. By the 1980s, histochemical
techniques had already identified focal mitochondrial
Complex IV (cytochrome c oxidase or COX) defi-
ciency in diseases due to pathogenic, nuclear-encoded
genes affecting mitochondrial function [4] or in normal
ageing of human hearts [5]. Later, it was found that
clonal expansion of mitochondrial (mt) DNA mutations
with age leads to COX deficiency in many human
tissues, and in vertebrate animal models of ageing [6].
Enzyme histochemical techniques have an advantage
in visualizing single cell dysfunction, compared with
other biochemical measurements of tissue homogenates
where the averaging of biochemical competence across
individual cells can mask cell-specific mitochondrial
defects. Quantitative analysis of COX activity has been
described by several groups, where the oxidation of
3,3’-diaminobenzidine (DAB) catalysed by COX is
monitored using microphotometric assays [7–9]. How-
ever, one drawback with this approach is the difficulty
in distinguishing between pathogenic loss of COX
activity versus cells with lower levels of COX activity
in tissues where cells display heterogeneous mito-
chondrial activity [10]. Alternatively, deficient COX
activity can be revealed using a double-labelling method
known as COX/SDH (cytochrome c oxidase/succinate
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dehydrogenase) histochemistry [11]. The COX/SDH
method cleverly reveals cells with normal mitochondrial
function in brown, through the oxidation of DAB, while
cells with deficiencies in COX activity are revealed in
blue. However, this dual colour hinders the detection
of low or intermediate deficiency levels, whose light
blue colour is obstructed by the predominant brown
pigments; therefore, detection and quantification of
COX deficiency remain incomplete [12].
Immunofluorescence techniques have also been
developed to quantify the presence of several subunits
of the respiratory chain complexes in tissues [13–15].
These analyses enable simultaneous evaluation of
multiple respiratory complexes in a single cell and are
semi-quantitative, providing sensitive detection of pro-
tein levels. The downsides of this approach are the costs
and effort of developing species-specific antibody sets,
and the detection of protein rather than a measurement
of enzyme function.
Here, we present a new enzyme histochemical assay
that exploits the competing redox reactions between
phenazine methosulphate (PMS), cytochrome c oxi-
dase, and nitrotetrazolium blue chloride (nitro blue tetra-
zolium; NBT). In 1989, Old and Johnson described
for a microphotometric assay, optimal protocols for the
histochemical assay of both SDH and COX activity
[7]. Their work was subsequently confirmed in mouse
tissues [16]. In addition, literature dating back to the
1950s describes the use of PMS for the reduction of
NBT [17,18], as well as the interaction of reduced PMS
with Complex IV [19–22]. Building upon these pre-
vious studies, we uncovered that the dual affinity of
PMS for either NBT or Complex IV can be exploited
to reveal COX-deficient cells without the use of DAB
and sequential reactions. Indeed, PMS is a strong elec-
tron carrier that transfers electrons from Complex II
to NBT; but in a complete system where mitochon-
drial COX activity is not inhibited, PMS preferentially
passes on electrons to molecular oxygen via electron
acceptors located in the COX subunits [21–23]. We
show here that the alternative COX/SDH histochemical
method – hereafter named nitrotetrazolium blue exclu-
sion assay (NBTx) – can efficiently reveal low levels of
COX deficiency in single cells. The strength of this new
assay is through the catalysis of formazan only where
COX activity is dysfunctional, leading to the direct
visualization of respiratory-deficient cells rather than
a reduction in the predicted COX activity. The NBTx
assay offers the unique opportunity to measure and
quantify COX deficiency directly and unambiguously.
Materials and methods
Ethics statement
All animal work was approved by the Lan-
desamt für Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen in accordance with Ger-
man and European Union regulations (Permits
84-02.042015.A103; 84-02.05.50.15.004). The use
of human tissues in this study followed the ethical
guidelines issued by the Newcastle and North Tyne-
side Local Research Ethics Committees (reference
09/H0906/75 and REC ref No 2001/188) and complied
with the Declaration of Helsinki.
Preparation of incubation media
Phosphate-buffered saline (PBS; 0.1 M, pH 7.0) was pre-
pared by mixing sodium dihydrogen orthophosphate
monohydrate (0.04 M) with disodium hydrogen phos-
phate anhydrous (0.06 M).
NBTx solution contained 5mg of NBT (Cat. No
N6876; Merck, Darmstadt, Hesse, Germany) dissolved
in 3.2ml of PBS, to which thawed stock solutions of
PMS (Cat. No P9625; Merck; 100 μl/ml, 2.0mM in
purified water) and sodium succinate (Cat. No S2378;
Merck; 100 ul/ml, 1.3 M in 0.1 M PBS) were added.
Final concentrations were 130 mM sodium succinate, 2
mM NBT, and 0.2 mM PMS, pH 7.0.
NBTx assay
Tissue preparation
Small pieces of heart tissue were quickly frozen in
2-methylbutane in a glass beaker cooled by immersion
in liquid nitrogen. Frozen tissues were stored at −80 ∘C
until ready to use. Testes and colons were frozen in
Tissue-Tek® O.C.T. compound (supplied by A Harten-
stein GmbH, Wuerzburg, Germany) immersed in liquid
nitrogen. Brain tissues were frozen slowly on dry ice.
Heart tissues were cut at 7 μm, whereas brains, skeletal
muscles, testes, and colons were cut at 10 μm using
a cryostat at −20 ∘C (OFT 5000; Bright Instruments,
Luton, UK), mounted on Superfrost Plus microscope
slides (Menzel, Thermo Scientific, Waltham, MA,
USA), and air-dried for 5–10min. Slides were kept
at −80 ∘C for at most a few months to avoid loss of
enzyme activity.
Staining protocol
Slides were taken out of the −80 ∘C freezer and thawed
briefly at room temperature on a slide holder without
a lid. Sections (three sections per slide) were then
covered with 1ml of PBS for 10min in an incubator
set at the desired temperature (1ml per slide). PBS was
discarded and replaced with 1ml of NBTx solution.
Incubation time and temperature varied according to
tissue type. Generally, the best results were obtained
with heart sections at 18 ∘C for 30min. Brain, skele-
tal muscles, and testes required a higher incubation
temperature (22–25 ∘C). Sections were then washed
briefly in purified water and dehydrated in an ethanol
series (2min in 50%, 75%, 96%, and 100%, followed
by an extra 5min in 100% ethanol). Finally, slides were
immersed for 5min in two changes of xylene before
being mounted on coverslips with Cytoseal™ (Thermo
Scientific, Darmstadt, Germany).
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Figure 1. PMS engages both the activity of Complex II and the activity of Complex IV. (A) Succinic dehydrogenase activity is detected in
wild-type heart tissues using sodium succinate as a substrate and NBT as a final electron acceptor (n= 3). (B) Blocking COX activity with
sodium azide does not prevent NBT reduction (n= 3). (C) Inhibiting the quinone-binding site of Complex II with atpenin A5 fully blocks
the transfer of electrons to NBT (500 nM, n= 3). Treatment of wild-type heart tissues with a solution containing 0.2mM PMS in addition to
sodium succinate and NBT significantly represses the catalysis of blue formazan crystals for (D) 10min, (E) 20min or (F) 30min incubation
at 18 ∘C (n= 5). (G, H) Complete reduction of NBT is rescued by chemically blocking COX with (G) sodium azide (1mM, 10min, n= 15) or
(H) potassium cyanide (1mM, 10min, n= 3). (I) Removing sodium succinate prevents formazan formation even in the presence of sodium
azide (10min, n= 3). Scale bar= 100 μm.
Inhibiting the respiratory chain
Sodium azide and potassium cyanide were dissolved
in water, malonate in 1 M sodium hydroxide and all
the other inhibitors in absolute ethanol at the following
concentrations: TTFA (1mM), atpenin A5 (0.1mM),
sodium azide (100mM), potassium cyanide (100mM),
rotenone (1mM), antimycin A (1mM), myxothiazol
(0.2mM), oligomycin (3mM), and malonate (6 M).
Stock solutions were stored at −20 ∘C and thawed
shortly before use. Inhibitors were added to PBS for
the preincubation time as well as to the NBTx solution
(rotenone, oligomycin, antimycin A, 1:500; myxothia-
zol, atpenin A5, TTFA, 1:200; sodium azide, potassium
cyanide, 1:100; malonate, 1:1000). Control conditions
contained 5 μl/ml of 100% ethanol or 1 μl/ml of 1 M
NaOH accordingly. All conditions retained a neutral pH
value between 6.9 and 7.2.
Results
NBTx assay
The NBTx assay involves only one colour (blue for-
mazan crystals from NBT) and is based on strong
biochemical competition between COX and NBT for the
acquisition of electrons from PMS (see reaction scheme
in Figure 2D). In COX-competent mitochondria, mini-
mal or no catalysis of formazan takes place and cells
remain colourless.
Using sodium succinate as a substrate and in the
absence of PMS, NBT reduction led to visible accu-
mulations of formazan – an indication of succinate
dehydrogenase activity (Figure 1A). This activity was
independent of Complex IV and no effect was observed
when its oxidative activity was blocked with sodium
azide (Figure 1B). However, formazan formation was
strongly blocked by atpenin A5 (Figure 1C), a potent
Complex II inhibitor [24].
Adding PMS has long been shown to improve the rate
of formazan catalysis, but its use in tissue sections is
known to be beneficial only with a COX inhibitor [21].
We therefore speculated that PMS is capable of trans-
ferring electrons to Complex IV and that this reaction is
favoured over its ability to reduce NBT. To confirm this,
we incubated heart sections with PMS (0.2mM), NBT
(2mM), and sodium succinate (130mM) in the absence
of any COX inhibitors. We observed that catalysis of
formazan was suppressed, demonstrating the inability of
PMS to reduce NBT in the presence of functional COX
activity. NBT molecules remained in their oxidized
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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form even after prolonged incubation (Figure 1D–F).
As expected, NBT reduction was fully restored using
sodium azide (1mM) or potassium cyanide (1mM), two
COX inhibitors (Figure 1G, H). Removal of sodium suc-
cinate prevented this effect (Figure 1I).
To confirm the specificity of Complex IV in prevent-
ing the transfer of electrons from PMS to NBT, we
attempted to restore NBT reduction with various elec-
tron transport chain inhibitors: Complex I (rotenone,
2 μM), Complex III (antimycin A, 1 μM and myxoth-
iazol, 1 μM), and inhibited ATP synthesis (oligomycin
A, 6 μM). None of the tested inhibitors could restore
NBT reduction (supplementary material, Figure S1). In
addition, the source of electron transfer from Complex
II to PMS was confirmed using antimycin A, atpenin
A5, and malonate (supplementary material, Figure S2).
Our results indicate that once reduced by Complex II,
PMS transfers electrons to COX or NBT, bypassing
the classical respiratory chain electron pathway. Thus,
in the presence of PMS, NBT reduction into formazan
only depended on the respective activities of Complex
II and COX.
As NBT reduction depends on the absence of COX
activity and because oxygen is a substrate of COX
and its concentration modulates COX catalytic activity
and substrate affinity [25], we hypothesized that for-
mazan formation could be influenced by oxygen pres-
sure and availability. This possibility was examined
with heart tissues of young (12weeks old) wild-type
mice in a chamber containing 2% oxygen. Low-oxygen
conditions led to rapid accumulation of formazan pig-
ments (Figure 2A). Likewise, elevated levels of for-
mazan deposition were noted in young hearts incubated
at high temperature, which we speculate increased the
reaction rate and caused a more rapid depletion of dis-
solved oxygen in the incubation media (Figure 2B).
High relative humidity also led to a slow deposition of
formazan crystals over time, suggesting again that oxy-
gen depletion is an important factor that influences the
outcome of the NBTx assay (Figure 2C).
Our findings point to a strong interplay between PMS,
Complex II, and Complex IV that is independent of the
rest of the respiratory chain, in agreement with previ-
ous reports [17–19,21]. In light of these observations,
we suggest a model where PMS interacts preferentially
with Complex IV, hindering its ability to deliver elec-
trons to NBT. In this scenario, NBT reduction serves
as an indicator of the loss of COX activity and thus
enables fast and sensitive detection of COX-deficient
cells (Figure 2D).
COX deficiency in mouse models
Based on the biochemical interactions described above,
we predicted that deficient cells within tissues of
transgenic mice with known COX deficiency would
be revealed by the deposition of formazan crystals.
In order to verify this, we analysed four different
transgenic mouse models previously characterised
and presenting different levels of COX deficiency
in the heart, namely: Lrpprc conditional knockout
(Lrpprc/CKMM-cre) [26,27], Surf1 knockout [28,29],
the PolgAD257A mtDNA mutator [30], and a mouse
heteroplasmic for an mtDNA m.5024C>T muta-
tion in the tRNAALA gene (mt-tRNAALA mice) [31].
Lrpprc/CKMM-cre conditional knockout mice have
an extensive loss of Complex IV in heart tissues, with
enzyme activities decreased by 90% at 12weeks of
age [26]. Surf1 knockout mice are reported to suffer a
loss between 30% and 50% of COX activity [27,28],
whereas mtDNA mutator mice lose around 25–30%
[32]. Mice harbouring the mt-tRNAALA mutation show
only sparse COX impairment [31]. The NBTx assay
revealed that in these mouse models, qualitative levels of
formazan crystal deposition correlated with the reported
mitochondrial COX deficiency (Figure 3). The darkest
blue pigments were seen in Lrpprc knockout heart
sections, followed by Surf1 knockout and the mtDNA
mutator mouse, with the lowest amount being observed
in mouse heart with the mt-tRNAALA mutation. The ease
at which COX-deficient cells are revealed was espe-
cially evident in the Surf1 knockout model (Figure 3C).
The relevance of this new approach is particularly
striking when compared side-by-side with sequential
COX/SDH or COX-only histochemistry. The NBTx
assay revealed even slight changes in COX activity,
with cells clearly distinguishable with a light blue tint,
whereas the same area in the COX/SDH serial section
revealed a puzzling presentation of colours that varied
from purple to brown or even greyish-blue, which may
lead to ambiguous interpretations and hinder proper
quantification [12]. Likewise, images of heart tissue
reacted to DAB only show COX-positive activity, which
is a disadvantage when assessing for the presence of
defective oxidative activity. For example, in the Lrpprc
knockout heart tissue (Figure 3A), we identified three
areas with as distinct intensity of formazan deposition
(labelled 1 to 3) in the NBTx assay. The same areas
in the COX/SDH section showed characteristic colour
variation but the light blue seen in the NBTx section of
area 1 was undetected when either the COX/SDH or the
COX-only histochemistry method was used. Further-
more, when COX deficiency was partial and equally
distributed across the tissue (as seen in a Surf1 knockout
mouse), COX-only histochemistry performed poorly for
revealing COX-deficient mitochondria (see Figure 3C).
Overall, the newly developed NBTx assay successfully
reveals COX-deficient mitochondria in tissue sections
and is more sensitive than previous methods.
MtDNA heteroplasmy in heart tissues
Cellular heteroplasmy describes the presence of
wild-type and mutated copies of mtDNA molecules
at a ratio that varies between organs and individual
cells. The increase of this ratio towards the mutated
variant is critical in the development of mtDNA-induced
mitochondrial disease or may be a risk factor in the
development of other age-related diseases [33]. Using
the NBTx assay, we were able to easily expose various
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 2. Competitive redox reactions. Wild-type hearts from 12-week-old mice were used to test the stability of a negative signal. (A)
Performing the NBTx assay in a hypoxic chamber (2% oxygen) leads to formazan deposition after 10min at room temperature. (B) Slight
variation in the temperature (between 18 and 25 ∘C) did not significantly increase formazan deposition, although high temperature (37 ∘C)
for heart tissues causes gradual accumulation of formazan crystals. (C) High relative humidity levels (65%) increase formazan deposition
in a healthy tissue and can influence the colourless background at a given temperature. N = at least 3 for each condition. (D) Proposed
interaction scheme: PMS is reduced within Complex II and subsequently re-oxidized by COX, leaving NBT in its colourless, oxidized form
(marked as ①). When the oxidative activity of Complex IV is either artificially blocked or deficient, PMS is efficiently passing electrons to
NBT, which triggers the formation of blue formazan crystals (marked as ②).
levels of COX deficiency in heart tissues of mice
with a point mutation in the mt-tRNAALA gene. Pups
were assayed at weaning for their relative levels of
the m.5024C>T mtDNA mutation using whole tissue
quantitative pyrosequencing. Even mice with relatively
high levels of the m.5024C>T mutation had low
numbers of detectable dysfunctional cells within the
tissue [31]. Heart sections treated with the NBTx assay
mixture revealed areas with low (clear), intermediate
(light blue), or high (dark blue) formazan deposition
(Figure 4A). We proceeded to isolate the different areas
using laser capture microdissection with subsequent
pyrosequencing to assay the relative m.5024C>Tmuta-
tion level within the laser captured area. As expected,
we observed a significant increase in the levels of the
m.5024C>T mutation in dark or light blue areas,
confirming a correlation between high relative levels of
this pathogenic mutation and the presence of deficient
COX activity (Figure 4B).
Quantification of COX deficiency
A mosaic distribution of affected cells within a given
tissue is a characteristic of many mitochondrial dis-
eases. Quantifying this variation would help to deci-
pher the correlation between cellular OXPHOS defi-
ciencies and disease progression. To demonstrate the
high sensitivity and reproducibility of the NBTx reac-
tion, we proceeded to evaluate the degree of blue for-
mazan crystals in wild-type heart tissues exposed to
increasing amounts of sodium azide. For this purpose,
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 3. COX-deficient cells in mouse heart tissues. Fresh-frozen heart tissues from mouse models with COX deficiencies are shown here
after COX/SDH, NBTx or COX alone. (A) Lrpprc knockout (n= 3); (B) mtDNA mutator (n= 3); (C) Surf1 knockout (n= 3); (D) mt-tRNAALA
m.5024C> T (n= 5); (E) wild-type (n= 5). The circles are identified areas with 1, low; 2, intermediate; or 3, high level COX deficiency. Scale
bar= 100 μm.
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Figure 4. Blue pigment density correlates with heteroplasmy and COX deficiency levels. (A) The high contrast that ensued from the NBTx
treatment of heart sections allows clear distinction of areas with low (clear), intermediate (light blue) or high (dark blue) formazan
deposition. Scale bar= 20 μm. (B) Each area was collected separately with a laser dissecting microscope and analysed using pyrosequencing
technology. Results of at least five pooled laser-captured microdissections for each colour, from four different mice carrying heteroplasmic
m.5024C> T mutation in the mt-tRNAALA gene. Single point values ±SD. Dunn’s multiple comparisons test, one-way ANOVA: clear versus
light blue (**p≤ 0.01) or clear versus dark blue (****p≤ 0.0001). Light blue versus dark blue values are not statistically different. (C) Heart
tissues were exposed to different concentrations of sodium azide (0, 5, 10, 15, 25, 50, 75, and 100 μM). Average blue intensity was calculated
using Fiji software and plotted against each sodium azide concentration. Numbers represent mean±SD from six images per animal (n= 3;
12-week-old males). Representative images for each azide concentration are shown under the graph. (D) Selected concentrations of sodium
azide were plotted showing the total pixel number from six images against each ROD value. Dashed lines are arbitrary ranges for background,
low, intermediate, and high deficiency, which we also transposed to tissues of the animal models. (E) Heart tissues of Lrpprc knockout, Surf1
knockout, mtDNA mutator, andmt-tRNAALA mice compared with age-matched wild-type tissue. Each line represents the results of replicate
experiments for different animals. (F) COX deficiency measured in three different fibre types [type II (oxidative, ox), type II (glycolytic, gly),
and type I] from the skeletal muscle of three mtDNA mutator mice. Each dot represents a single cell, with 15 cells per column, with mean
and standard deviation shown. (G) Oxidative type II fibres were used to compare % COX deficiency with the value of SDH activity (relative
OD; mean value of three replicates with standard deviation) obtained for each single cell.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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a simple and accessible workflow was developed using
images captured with an upright microscope and subse-
quently analysed using Fiji, a free image processing soft-
ware package (supplementary material, Table S1). Con-
centrations as low as 5 μM induced a small, detectable
change in relative optical density (ROD) measurements,
followed by a gradual increase which plateaued at
about 100 μM. Linearity was detected in the range of
5–25 μM sodium azide (Figure 4C). Completely block-
ing mitochondrial activity with 1mM sodium azide sat-
urated the image with an average ROD of 252±1.5
(not shown).
The variation in cellular dysfunction within the tis-
sue was lost when the average ROD was calculated
rather than the single cell values. We reanalysed the
images from the sodium azide-treated heart tissues and
extracted the total number of pixels for each inten-
sity level. Figure 4D shows a distribution curve with an
important distribution of values across the range, but
interestingly each sodium azide concentration created
a unique and consistent curve. Within a cell, variations
in the density of formazan deposition between subcel-
lular regions, as well as spaces between cells, might
explain this distribution (see close-up images in supple-
mentary material, Figure S3). We arbitrarily assigned a
range of blue optical densities which would represent
low, intermediate, and high levels of COX deficiency,
with the goal of establishing the distribution levels
within our animal models. Plotting the number of pix-
els versus the blue ROD values for the four different
animal models resulted in similar curves (Figure 4E).
Moreover, the data for each animal were plotted indi-
vidually to assess inter-individual variability for each
genotype.
The new NBTx assay accurately reveals COX defi-
ciency with a very high sensitivity. The absence of
brown pigments in functional mitochondria led to a
clearer and consistent distinction of blue intensities.
Our image analysis enables the extraction of valuable
information such as COX deficiency levels – as an aver-
age ROD for the entire tissue or as a spectrum within
the tissue (number of pixels per ROD); and variability
within one specific genetic line [for example, we found
that mtDNA mutator mice as well as Surf1 knock-
out mice varied substantially between each animal,
whereas Lrpprc knockout and tRNAALA mice tended to
be consistent (Figure 4E)].
In skeletal muscle tissue, we performed single cell
analysis to look at the variability of the NBTx sig-
nal in fibre types which naturally vary in the levels
of mitochondrial activity. Consecutive serial sections
were used to distinguish fibre types with myosin ATPase
reactions at pH 4.3 and 10, in addition to a section
for histochemical assay of SDH activity. The inten-
sity of formazan deposition, as measured in the SDH
assay, was used to distinguish fibre types of similar
mitochondrial activity (supplementary material, Figure
S4 and Table S2). Three different types of fibres in
mtDNA mutator mice hind limb muscle (gastrocnemius
and soleus) – fibre type I, type II (oxidative), and type
II (glycolytic) – were identified and used to make an
evaluation of each fibre’s characteristic COX impair-
ment.We found no significant difference in SDH activity
between wild-type and mtDNA mutator animals (sup-
plementary material, Figure S4E). Our results show
that fibre types with greater oxidative activity [types II
(oxidative) and I] show larger decreases in COX activity
than the glycolytic fibres (Figure 4F). Also, measure-
ments of individual cells from the same fibre type show a
variation in COX impairment that does not correlate with
the values of the measured SDH activity (Figure 4G).
NBTx assay of other tissues
The suitability of the NBTx assay in other mouse
organs was investigated. We were particularly inter-
ested in looking at brain sections, as this organ had
proven to require extensive and laborious optimiza-
tion with traditional COX/SDH [11,12]. NBTx assays
on brain sections of Surf1 knockout mice revealed an
easily observable deposition of blue pigments across
the tissue (Figure 5A, B), whereas we found the serial
sections of control and mutant brain sections after a
COX/SDH reaction difficult to interpret (Figure 5A, B,
second panel). Similar to the heart, the resulting colour
was similar to unoptimized conditions, where DAB
incubation was insufficient to block SDH activity in
normal brain controls (Figure 5A, 20min COX, third
panel). Within these COX/SDH sections, it appeared
as though brown deposits within functional mitochon-
dria were mixed with blue deposits, rendering the col-
oration of Surf1 knockout brain sections difficult to
interpret. In contrast, detection of COX-deficient cells
against the background of COX-functional cells that
lack any coloration provided excellent contrast with the
NBTx assay.
We proceeded with the evaluation of a few other
mouse organs that are commonly used in our laborato-
ries to test how other tissues respond to the NBTx assay.
Deficient COX activity was easily revealed in colonic
crypts and skeletal muscles (Figure 5C, first and second
panels). Furthermore, small developing sperm cells in
the testis were also successfully detected with the NBTx
method (Figure 5C, third panel). In the latter, strong
pink discoloration was seen in addition to the blue crys-
tals and was interpreted as a half-reduced intermediate
which is partly washed away in ethanol [34,35].
NBTx assay to study Drosophila melanogaster
The fruit fly Drosophila melanogaster is becoming
more commonly used as an alternative animal model for
mitochondrial research, yet histochemical techniques
are lacking for these models [36]. The fly Lrpprc2
gene is one of two homologs of the mouse Lrpprc
gene, which is involved in coordinating mitochondrial
gene translation, and Lrpprc2 knockout or knockdown
leads to a drastic loss of respiratory chain complexes
[37]. The DmPolγA flies are flies trans-complementing
two deleterious mitochondrial polymerase gamma
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 5. NBTx assay in a variety of tissues. (A) Brain sections of wild-type mice are shown stained either with the NBTx or the COX/SDH
method. (B) Consecutive section of brain Surf1 knockout mice (n= 3). Scale bar= 500 μm. (C) Colons and testes of mtDNA mutator mice
as well as skeletal muscles (SKM) of Surf1 knockout mice (n= 3). Scale bar= 100 μm. (D) Skeletal muscles from the thorax of Drosophila
melanogaster stained for 10min at 18 ∘C. Representative images of five flies per genotype. Scale bar= 100 μm.
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mutant alleles (the exo-deficient PolgAD257A and the
processivity-impairing PolgAH1134A alleles), which
present no obvious pathogenic phenotypes [38]. How-
ever, using the NBTx assay, we were able to observe
mild deficiency in COX activity. The high Complex
IV content in the fly thoracic muscles required a short
incubation time of only 10min at 18 ∘C to produce
strong formazan deposition in the Lrpprc2 RNAi fly.
DmPolγA muscles revealed mild formazan deposition,
whereas wild-type healthy muscles remained colourless
under these conditions (Figure 5D).
NBTx assay in the diagnosis of mitochondrial
diseases
The sequential COX/SDH histochemical assay is uni-
versally applied in pathology laboratories as part of the
diagnostic work-up of human tissue, including muscle
biopsies, to identify COX-deficient cells [39]. To test
the applicability of the NBTx method in human diag-
nostics, we compared serial sections of NBTx images
against sequential COX/SDH and COX-only reactions
for a variety of human biopsy samples (Figure 6).
Seven distinct genotypes were used to evaluate human
skeletal muscles as well as seven samples of heart tissues
(supplementary material, Figures S5 and S6). We found
that regardless of the genetic defect (mtDNA mutations,
Figure 6A or nuclear gene mutations, Figure 6B, C),
the NBTx assay successfully exposed the full range of
COX-deficient cells, as predicted from the COX/SDH
sections, with the advantage that low and intermediate
levels of dysfunction were distinguished with a quantifi-
able variation in blue intensity. In contrast to the classical
COX/SDH reaction, the NBTx assay does not identify
cells with functional mitochondria, regardless of the
COX activity level (Figure 6A, marked I and II), but, as
seen in the mouse, reveals dysfunctional COX activity
with the accumulation of a blue formazan pigment of
varying intensity (Figure 6A, marked III, IV, and V).
Thus, NBTx successfully detected COX-deficient cells
in all three types of tissue in patterns consistent with
the COX/SDH method. These data show that the NBTx
assay is suitable for human diagnostic work, revealing
high-contrast sections that allow for quantification and
rapid diagnosis.
Discussion
Accurately quantifying COX impairment at the cellular
level will contribute to our understanding of the role
of respiratory chain defects in mitochondrial disease
processes and the implication of mitochondrial dys-
function in age-related diseases. The currently available
methods for cell-specific detection, such as COX-only
histochemistry, immunolabelling of mitochondrial com-
plex subunits or the sequential COX/SDH assay, either
involve many steps or are limited to the detection of high
levels of COX deficiency, failing to clearly expose low
or intermediate levels. We have shown that deficiency
in cytochrome c oxidase activity can be detected with
the simple reduction of NBT. We have demonstrated
here that the NBTx method exploits tightly competing
biochemical interactions between PMS, NBT, and
Complex IV to evaluate the integrity of COX activity
in an enzyme histochemical assay, eliminating the need
for DAB. The presence of DAB has been reported to
interfere with certain assays, such as real-time qPCR
[12], and therefore the capacity to reveal COX-deficient
cells without DAB is advantageous in many ways. The
assay generates images with a high contrast between
COX-deficient and COX-competent cells, and not only
reduces the overall cost but is also quick and allows
clear identification of cells harbouring even mildly
COX-deficient mitochondria. This single-colour reac-
tion has the added advantage that simple automation
and quantitative analysis are possible, without having
to rely on comparing the activity levels between sam-
ples (as is done with COX histochemical methods or
immunohistochemistry).
The one-step NBTx assay eliminates the confounding
results observed with the sequential COX/SDH reaction
of intermediate COX deficiency [12]. Unarguably,
the strong contrast of blue COX-deficient cells over a
clear background of fully functional cells in the NBTx
assay offers an improvement over previous methods.
Our results on brain sections of Surf1 constitutive KO
mice illustrate how intermediate levels of COX activity
are easily identified. Beyond primary mitochondrial
disease, loss of mitochondrial activity in the brain is a
domain of investigation in normal ageing processes or
age-related diseases such as Alzheimer’s or Parkinson’s
disease [40–42]. Reduction of COX activity in aged
brain tissue has been reported in humans, rodents,
and monkeys using COX cytochemical or immuno-
histochemical methods [43–46]. Analysis of DAB
accumulation or detection of immunolabelled Com-
plex IV subunits is challenging because both require
imaging at very precise brain areas and comparing
those areas between samples. This limits the field
of view to precisely where investigators make their
measurements and given the heterogeneous distribu-
tion of mitochondrial activity in the brain, assessment
of loss of enzyme activity in the nervous system
is difficult.
Based on the successful identification of COX defi-
ciency in human tissues of a wide range of genetic back-
grounds, we set the basis for establishing the NBTx
assay within the diagnostic workflow. In addition, we
have shown here the potential for the acquisition of
quantitative data, which will support research on mito-
chondrial disease mechanisms and also in the evaluation
of therapeutic approaches. We have also demonstrated
that the method is easily re-optimized for a variety of
mouse or human tissues and smaller model organisms
such as the fly Drosophila melanogaster, and we antici-
pate that the advantages of this method will benefit many
in the field of mitochondrial research.
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Figure 6. Human tissues analysed using the COX/SDH, NBTx or COX histochemical methods. (A) Skeletal muscle tissue with a novel
m.16015 T> CMTTP mutation. Roman numerals indicate individual cells with (I) no COX deficiency, high COX activity; (II) no COX deficiency,
low COX activity; (III) mild COX deficiency, low SDH activity levels; (IV) mild COX deficiency, mild SDH activity levels; and (V) strong COX
deficiency, high SDH activity levels. (B) Section of skeletal muscle from a patient with identified nuclear gene p.(Arg371Trp) TWNK (formerly
PEO1) mutation. (C) Human heart tissue, p.Asn238Ser;c.829_830+ 2her_delGAGT RMND1 mutations. (D) Sections of colonic tissue from
a patient with no known mitochondrial disease. COX-deficient colonic crypts are detected in elderly patients (n= 2; 78 and 72 years old).
Scale bar= 100 μm.
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